ChemDiv Announces Expansion of Multi-Year Hit Identification Collaboration with Janssen
Jan 23, 2018, 09:06 ET
SAN DIEGO, Jan. 23, 2018 /PRNewswire/ -- ChemDiv, Inc. announced at the 36th Annual J.P. Morgan Healthcare Conference the expansion of its hit identification collaboration with Janssen Research & Development, LLC (Janssen) and extending it into finding potent anti-infective drug candidates. Broadening the original multi-target focus of the collaboration even further, ChemDiv will use its quarter-century expertise in early drug discovery and seasoned integrated discovery platform to deliver a pipeline of novel high-quality hit series in the area of infectious diseases. Janssen is granted access to ChemDiv's discovery chemistry platform, while ChemDiv will receive additional R&D fees and will be eligible for success-based milestone payments for identification of novel active chemical series.
"ChemDiv has had a number of highly successful collaborations with Janssen in multiple therapeutic areas and we are very proud to see our long-term partnership thrive even further. It showcases our ability to systematically deliver scientific and commercial value to industry leaders," comments Rouslan Michtchenko, Global Head of Business Development at ChemDiv. "Collaborative risk sharing under this strategic arrangement fosters R&D productivity, minimizes cost of acquiring research resources, while appropriately rewarding ChemDiv based on the productivity of our chemistry. A radical shift from the traditional unit-pricing models and fee-for-service arrangements, this model is far more effective as our long-standing partnership demonstrates – it allows us to continuously deliver value to our partners, and helps them develop novel effective treatments for unmet medical needs around the globe."
About ChemDiv and ChemDiv Research Institute:
ChemDiv is a fully integrated discovery and development CRO serving the life science industry for 27 successful years. The ChemDiv Research Institute R&D facilities are located at Torrey Pines Center in San Diego, CA, ChemRar High-Tech Center and Skolkovo Life Science Cluster in Moscow. ChemDiv accelerates and enables pharma and biotech R&D programs from research concepts to clinic and market registration, covering the complete range of disciplines, in CNS, oncology, inflammation, cardio metabolic, infectious diseases, and other therapeutic areas. Visit www.chemdiv.com for more information.
Media Contact: Ronald Demuth, [email protected], 858-724-0581
SOURCE ChemDiv